Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder

When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of clinical readouts in blood disorders it is expecting as the impetus.